Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.

Kirtschig, Gudula; van Meurs, Tim; van Doorn, Remco

Kirtschig, Gudula; van Meurs, Tim; van Doorn, Remco.

Affiliation

Kirtschig G; Centre of Evidence-Based Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. g.kirtschig@gmail.com.

Acta Derm Venereol ; 95(1): 83-5, 2015 Jan.

Article in En | MEDLINE | ID: mdl-24696093

Subject(s)

Aminoquinolines/administration & dosage; Antineoplastic Agents/administration & dosage; Hutchinson's Melanotic Freckle/drug therapy; Skin Neoplasms/drug therapy; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminoquinolines/adverse effects; Antineoplastic Agents/adverse effects; Biopsy; Drug Administration Schedule; Female; Humans; Hutchinson's Melanotic Freckle/pathology; Imiquimod; Male; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms/pathology; Time Factors; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Hutchinson's Melanotic Freckle / Aminoquinolines / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Acta Derm Venereol Year: 2015 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google